0000950170-23-056944.txt : 20231031
0000950170-23-056944.hdr.sgml : 20231031
20231031170015
ACCESSION NUMBER: 0000950170-23-056944
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231027
FILED AS OF DATE: 20231031
DATE AS OF CHANGE: 20231031
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nelson Sonja
CENTRAL INDEX KEY: 0001674905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-56600
FILM NUMBER: 231365454
MAIL ADDRESS:
STREET 1: C/O MOTUS GI HOLDINGS, INC.
STREET 2: 1301 EAST BROWARD BOULEVARD, 3RD FLOOR
CITY: FT. LAUDERDALE
STATE: FL
ZIP: 33301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ambrx Biopharma, Inc.
CENTRAL INDEX KEY: 0001990550
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 875-2400
MAIL ADDRESS:
STREET 1: 10975 NORTH TORREY PINES ROAD
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: New Ambrx Biopharma Inc.
DATE OF NAME CHANGE: 20230818
4
1
ownership.xml
4
X0508
4
2023-10-27
0001990550
Ambrx Biopharma, Inc.
AMAM
0001674905
Nelson Sonja
C/O AMBRX BIOPHARMA, INC.
10975 N TORREY PINES ROAD
LA JOLLA
CA
92037
false
true
false
false
Chief Financial Officer
true
Common Stock
2023-10-27
4
S
false
12778
9.82
D
130079
D
Reflects an adjustment in connection with the holding company reorganization resulting in Ambrx Biopharma, Inc. ("Ambrx") becoming a Delaware corporation (the "Domestication"). Pursuant to the transactions contemplated by the Domestication, each Ordinary Share of the previous holding company (Ambrx Biopharma Inc., a Cayman Islands company) converted into one-seventh (1/7th) of a share of common stock of Ambrx. Represents Restricted Stock Units ("RSUs") payable in Ambrx common stock granted to the Reporting Person as previously disclosed.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of the RSUs. The sale is mandated by Ambrx's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The sale is being made pursuant to the Reporting Person's effective 10b5-1 plan.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.99. The Reporting Person undertakes to provide to Ambrx, any security holder of Ambrx or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Sonja Nelson
2023-10-31